FCCC LOGO Faculty Publications
Davis SL , Cardin DB , Shahda S , Lenz HJ , Dotan E , O'Neil BH , Kapoun AM , Stagg RJ , Berlin J , Messersmith WA , Cohen SJ
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Invest New Drugs. 2019 Jul 23
Back to previous list
Abstract
Vantictumab is a fully human monoclonal antibody that inhibits Wnt pathway signaling through binding FZD1, 2, 5, 7, and 8 receptors. This phase Ib study evaluated vantictumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic adenocarcinoma. Patients received vantictumab at escalating doses in combination with standard dosing of nab-paclitaxel and gemcitabine according to a 3 + 3 design. A total of 31 patients were treated in 5 dosing cohorts. Fragility fractures attributed to vantictumab occurred in 2 patients in Cohort 2 (7 mg/kg every 2 weeks), and this maximum administered dose (MAD) on study was considered unsafe. The dosing schedule was revised to every 4 weeks for Cohorts 3 through 5, with additional bone safety parameters added. Sequential dosing of vantictumab followed by nab-paclitaxel and gemcitabine was also explored. No fragility fractures attributed to vantictumab occurred in these cohorts; pathologic fracture not attributed to vantictumab was documented in 2 patients. The study was ultimately terminated due to concerns around bone-related safety, and thus the maximum tolerated dose (MTD) of the combination was not determined. The MAD of vantictumab according to the revised dosing schedule was 5 mg/kg (n = 16).
Notes
1573-0646 Davis, S Lindsey Cardin, Dana B Shahda, Safi Lenz, Heinz-Josef Dotan, Efrat O'Neil, Bert H Kapoun, Ann M Stagg, Robert J Berlin, Jordan Messersmith, Wells A Cohen, Steven J Not applicable/OncoMed Pharmaceuticals Journal Article United States Invest New Drugs. 2019 Jul 23. pii: 10.1007/s10637-019-00824-1. doi: 10.1007/s10637-019-00824-1.